⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

April 1, 2024Open Access

Supplemental Table 3 from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax

Alexandre Bazinet Sai Prasad Desikan Ziyi Li Juan José Rodríguez‐Sevilla Sangeetha Venugopal Samuel Urrutia Guillermo Montalban‐Bravo Koji Sasaki Kelly S. Chien Danielle Hammond Rashmi Kanagal‐Shamanna Irene Gañán‐Gómez Tapan M. Kadia Gautam Borthakur Courtney D. DiNardo Naval Daver Elias Jabbour Farhad Ravandi Hagop M. Kantarjian Guillermo Garcia‐Manero

View Full Paper

Ask AI

Bookmark

Share

Abstract

Supplemental Table 3: Overall response rate and complete remission rate by venetoclax dose and schedule.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Bazinet et al. (2024) studied this question.

synapsesocial.com/papers/68e712c7b6db64358768bc38 https://doi.org/10.1158/1078-0432.25515451.v1

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplemental Table 3 from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax2024
2Supplemental Table 2 from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax2024
3Supplemental Table 2 from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax2024
4Supplemental Figure 1 from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax2024
5Supplemental Figure 1 from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax2024

Supplemental Figure 3 from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax2024
Supplemental Figure 3 from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax2024
Supplemental Figure 2 from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax2024